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Introduction
Colorectal cancer (CRC), an aggressive malignant disease with a poor prognosis, is the fourth leading cause of cancer-related death in the industrialized world [1] . A large body of evidence indicates CRC cells' self-sufficiency in growth signals, their ability to escape from apoptosis, and their tendency toward tissue invasion and metastasis [2] . Moreover, chemotherapy treatments for CRC are often ineffective because of the intrinsic chemoresistance of these tumors [3] . Therefore, it is imperative to develop more effective drugs. Apoptosis is a morphologically and biochemically driven process, while impaired apoptosis and defects in the regulation of the cell cycle are hallmarks that contribute to cancer growth and aggressiveness [4] . Recent studies have suggested that phenolic phytochemicals having antioxidant activity should shortcircuit the signaling events and eventually inhibit CRC cell proliferation [5] . Previous study has shown that Camptothecin (CPT) is an alkaloid originally isolated from the bark and stem of Camptotheca acuminata, a tree native to China [6] . As described in detail previously that CPT induces cancer cells apoptosis, interacts with DNA to form a complex, and reduces DNA, RNA, and protein synthesis [7] . A number of furo [2,3-b] quinoline derivatives, such as CIL-102, have also been synthesized and have been found to exhibit antitumor effects [8] . The survival curve showed that CIL-102 may possess antitumor activity against cancer cells of the prostate and breast, as well as those found in leukemia and cervical carcinoma [9] . This is studied by the inhibition of tubulin polymerization followed by apoptosis processed via the caspase and non-caspase pathways [10] . However, little is known about the anti-colorectal cancer mechanism. Similarly, the mechanism by which CIL-102 initiates cell death and cell cycle arrest and by which the signaling cascades become activated remains poorly understood.
Chemopreventive compounds may induce cell apoptosis through the regulation of the MAPK pathways [11] . The mitogen-activated protein kinases (MAPKs) are a family of protein kinases that transfer signals of stimuli from the cell membrane to the nucleus [12] . Intracellular signaling pathways for apoptosis have mainly focused on two cascades, the extrinsic and intrinsic pathways, which both lead to the kinase cascade [13] . The extrinsic pathway is triggered at the plasma membrane by the activation of TNFR1/Fas. This results in the cleavage of cytosolic BID to truncated tBID by caspase-8, which translocates to the mitochondria [14] . The kinase-signaling cascade, the intrinsic pathway, was originally identified as an important pathway in the transduction of apoptotic signals initiated by stress or anticancer drug stimuli [15] . The release of cytochrome c from the mitochondria represents a critical event in initiating the activation of caspase 9 and caspase 3 [16] . Herein, the effect of CIL-102-mediated apoptosis and the triggering mechanism of the signaling pathways on human CRC remain unclear.
Proliferation of CRC cells usually fails to control checkpoints, one of which is the G2/M phase checkpoint [17] . The inhibitors of the cell cycle progression stimulatory signaling pathway have been shown to target cdc2, cyclin B1 and cyclin A, which are required for mitotic entry in mammalian cells, thereby suppressing cdc2 activity by inhibiting the accumulation of cyclin B1 mRNA and protein [18] . DNA damage also correlates with the inhibition of cdc2-cyclin B kinase activity through clinical treatment with anti-microtubule drugs to inhibit colorectal cells' proliferation and induce cell growth arrest [10, 17] . A cyclin-dependent kinase inhibitor called p21/WAF1 plays an important role as a tumor suppressor [19] . With respect to cell-cycle regulation, p21 has been reported to induce G2/M arrest by blocking CDK1 activity. It was suggested that p21/WAF1 and Gadd45 may participate in a coordinated manner in a DNA damage response [20] . Evidence has emerged that GADD45, a cell cycle regulated nuclear protein, disrupts the interactions of Cdc2 with cyclin B1 and that GADD45 may thus induce G2/M arrest. Therefore, it is imperative to investigate how diet prevents the malignance and progression of CRC [21] . In addition to previous strategies that can reduce CRC risk, dietary phytochemicals are emerging as a promising chemoprevention approach. The cell cycle regulation and the in vivo anti-tumor effect of the 9-anilinofuroquinoline derivative, CIL-102, are not clearly known in CRC. GADD45 and p21, therefore, may represent a unique target for drugs that induce cell cycle arrest, apoptosis, and differentiation such as CIL-102.
The 9-anilinofuroquinoline derivative, CIL-102, has been used clinically as an antiseptic drug, which was not a natural product and, is impossible to be found in the bark and stem of Camptotheca acuminate [22] . Numerous studies have suggested that it possesses anticancer and chemopreventive properties and inhibits the proliferation of tumor cells [23, 24] . Our recent study showed that CIL-102 inhibited the proliferation and the invasiveness property in glioma cells and altered the expression of genes related to cell cycle regulation by activating the ERK1/2 and Cdc25cSer 216 cell-cycle-related proteins and inducing ROS generation [23] . However, the mechanism by which CIL-102 induces apoptosis remains poorly understood. In our study, we first investigated whether CIL-102 had a dose-dependent effect on the cytotoxicity of CRC. It was found to cause apoptosis, which was preceded by the sustained activation of JNK, activated caspase-8 and cleaved Bid protein to its truncated form, t-Bid, and caused the release of cytochrome c. It then directly activated the downstream effector caspases such as caspase-3 and caspase-9. Our results strongly suggested an essential role for the JNK1/2/NFκB p50/ p300/CBP as well as the p21 and GADD45 pathways during the execution of cell cycle G2/M arrest, which might be controlled by inhibiting CRC cell proliferation and which seems to play a role in CIL-102-induced apoptosis.
Materials and Methods
Chemical reagents and antibodies
All culture materials were purchased from Gibco (Grand Island, NY, USA).
, and mTOR inhibitor (rapamycin) were purchased from Sigma (St. Louis, MO, USA). Mouse monoclonal antibodies against cyclin A, cyclin D1, cyclin E, cyclin B1, acetylation of H3 (Ac-Histone H3) at Lys 9 and Lys 14, cytochrome c, caspase-3, -8, -9 and β-actin were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA 
Cell culture
Human colon cancer cell line DLD-1 (CCL-221) and human colorectal carcinoma cell line HCT-116 (CCL-247) were purchased from American Type Culture Collection (ATCC). DLD-1 cells were cultured in RPMI 1640 medium composed of 10% fetal calf serum (FCS) (S0113; Biochrom KG, Berlin, Germany) and 1% antibiotics (100 units/mL of penicillin and 100 μg/ mL of streptomycin) (Sigma Chemicals, St. Louis, MO, USA) and incubated at 37˚C with 5% CO2. We purchased passage number 1 of human normal astrocytes (HNA) from ScienCell Research Laboratories (Carlsbad, CA) and cells were grown. Adhered cells were washed twice with PBS. HCT-116 was cultured in DMEM supplemented with 10% heat-inactivated newborn calf serum at 37˚C in a humidified 5% CO2 incubator [25] .
Cell growth and proliferation assay
The previously reported MTT quantitative colorimetric assay was previously described [23, 26] . Cells were seeded and incubated with the various agents. Thereafter, the medium was changed, and cells were incubated with MTT (0.5 mg/mL) for 4 h. The viable cell number was directly proportional to the production of formazan, which was measured spectrophotometrically (λ = 563 nm) after solubilization with isopropanol. Cell growth was determined by counting the cells at the indicated time points with a Coulter counter, combined with a trypan blue (0.2%) exclusion assay [27] .
Apoptosis assay and cell cycle distribution analysis
Changes in cell morphological characteristics during apoptosis were examined using fluorescence microscopy of 4 0 ,6-diamidino-2-phenylindole (DAPI)-stained cells, as described in detail previously [23, 27] . The monolayer of cells was fixed with 4% paraformaldehyde for 30 min at room temperature. The fixed cells were permeabilized with 3 treatments in 0.2% Triton X-100 in phosphate-buffered saline, followed by incubation with 1 μg/mL of DAPI for 30 min. The apoptotic nuclei were detected under 200× magnification using a fluorescent microscope with a 340/380 nm excitation filter and were scored according to the percentage of apoptotic nuclei found in samples containing 200 to 300 cells.
Cell viability, as previously reported by Annexin V-FITC/ propidium iodide (Biosource International, USA), used to quantify the percentage of cells undergoing apoptosis. and the cells were washed prior to FACS analysis and Cell Quest software was used (Becton Dickenson). The results were presented as a percentage of the fluorescent intensity compared with the control sample. Data were analyzed with CellQuest and WinMDI software. The apoptotic cells (V+/PI-) were measured by the fluorescence-activated cell sorter analysis in a FACS analyzer (Becton Dickinson). The data represented three independent experiments [26] .
Cell-cycle distribution was analyzed using flow cytometry. Cells stained with propidium iodide were analyzed with a FACScalibur™ (Becton Dickinson), and the data were analyzed using a mod-fit cell cycle analysis program [26] .
proliferation potential involving the signaling pathway. We treated DLD-1, HCT-116 and normal human colonic epithelial cells (HCoEpiC) with a range of CIL-102 doses for 24 h and examined them by MTT assays. CIL-102 treatment resulted in a dose-dependent loss of cell viability, as shown in Fig 1A. After treatment with 1 μM CIL-102 for 24 h, 55% and 50% of DLD-1 and HCT-116 cells (P < 0.01), respectively, survived in culture (Fig 1A) . However, CIL-102 did not significantly show cytotoxic effects in HCoEpiC cells. In addition, to verify CIL-102-induced cell toxicity, we examined the changes in cell morphology after CIL-102 exposure. Fig 1B shows that exposure to erinacine A for 24 h caused DLD-1 cells to morphologically display features of cell shrinking, with the growths to which they belong becoming smaller.
CIL-102 induces apoptosis and cell cycle G2/M arrest in DLD-1 CRC cells
The addition of Annexin-V stain has led to similar findings (Fig 2) . The extent of apoptosis of CIL-102 induction was quantified as a percentage of annexin V-positive cells and was shown as 12 ± 4 (6 h), 13 ±2 (12 h), and 26 ± 3% (24 h), respectively. Both experiments proved that CIL-102 elicits apoptosis. Cell cycle distribution analysis showed that CIL-102 induces cell cycle G2/M arrest in DLD-1 cells. As demonstrated in Fig 3, following a 24 h treatment with 1 μM CIL-102, the percentages of G2/M phase cells increased to 22 ± 2 (6 h), 35 ±2 (12 h), and 52 ± 2% (24 h), respectively. These results suggest that CIL-102 induces G2/M arrest in a timedependent manner.
Activation of apoptosis pathway by CIL-102 in DLD-1 cells
Recent theories pertain to the persistent extrinsic apoptosis pathway involved in the binding of a ligand to one of the tumor necrosis factor families of death receptors, followed by the activation of caspase-8 by phytochemicals. It was concluded that the intrinsic pathways are linked through the ability of caspase-8 to cleave Bid, which in turn leads to the release of cytochrome c from the mitochondria pathways. To elucidate the events of CIL-102-stimulated DLD-1 cell death, we examined kinetic studies to evaluate Fas-L, caspase 8 and t-BID expression as well as caspase 3 and caspase 9 during a 24 h period. As shown in Fig 4, CIL-102 was shown to cause detectable and increased levels of Fas-L and cytochrome c in the cytosol and a time-dependent cleavage of Bid for 24 h. Treatment with CIL-102 resulted in proteolytic processing of the caspase 3 and caspase 9 (36 kDa) into two smaller subunits.
Expression of p21 and GADD45 as well as NFκB p50/p300/CBP signaling pathways by CIL-102 in DLD-1 cells Numerous investigations have shown the among proteins known to the transcriptional coactivator p300/CBP deserves DNA damage that control G2/M regulation and delayed entry into mitosis correlation with cdc2/cyclin B1 association [29] . To demonstrate the effect of CIL-102 on the cell-cycle-related proteins and the kinase-signaling pathway, we assessed whole-cell lysates from erinacine A-treated DLD-1 cells by Western blot analysis using antibodies against the expressed forms of p21 and GADD45 as well as NFκB p50/p300/CBP. As shown in Fig 5, treatment of DLD-1 cells with CIL-102 resulted in the marked expression of p21 and GADD45 as well as NFκB p50/p300/CBP compared with the control for a period of time points. In addition, the analysis showed a marked downregulation of cdc2/cyclin B1 association after CIL-102 treatment of DLD-1 cells in a time-dependent manner. of both kinases was observed after treatment with CIL-102 and was markedly sustained for at least 6 h. ERK1/2Thr 202 /Tyr 204 was found to be not constitutively activated, but it exhibited no changes after CIL-102 treatment. To investigate the roles of the JNK1/2 signaling pathway and the NFκB p50/p300 pathways in CIL-102-induced apoptosis and cell cycle retardation, we exposed DLD-1 cells to CIL-102 and then co-treated them with the specific JNK inhibitor Whole cell lysate proteins were prepared and analyzed by western blot, with β-actin serving as loading control. CIL-102 for the indicated times were analyzed by 10% SDS-PAGE and subsequently treated with antibodies against p21, GADD45, p50 NFκB, p300/CBP and CREB. The association of cdc2 with Cyclin B were determined by immunoprecipitation followed by western blot with antibody.
Fig 6. Effect of the kinase inhibitors in blocking CIL-102-induced cell cycle G2/M arrest and apoptosis-related protein. (A)
The expression levels of phosphorylation and protein levels of JNK and ERK, after treatment with CIL-102. DLD-1 cells were treated with CIL-102 for the indicated time points. Total cell lysates were analyzed by SDS-PAGE and subsequently immunoblotted with antisera. (B) DLD-1 were incubated with various concentrations of the specific JNK1/2 inhibitor SP600125, NFκB inhibitor PDTI or the p300/CREB-Binding Protein inhibitor C646 for 1 h. Next, the cells were treated with CIL-102 for 12 h. Total cell lysates of cells treated with or without CIL-102 for the indicated time were extracted, and the expression of p21, GADD45, p50 NFκB, Histone H3 (K4) as well as The association of cdc2 with Cyclin B were determined, as described in "Materials and methods". Protein levels were quantified by densitometric analysis with the ratio of untreated control being set 1 fold. The quantitative data were presented as the mean of three repeats from one independent experiment. The data were presented as mean ± SD of three independent experiments. *P<0.05, compared to the control group.
doi:10.1371/journal.pone.0168989.g006
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cycle G2/M arrest in DLD-1 cells. Furthermore, it was found that the expression of these proteins, p21 and GADD45, and the acetylation of H3 (Ac-Histone H3) at Lys 9 and Lys 14 clearly increased with the use of CIL-102, compared with the control. This data significantly demonstrated that CIL-102 inhibited cell growth and decreased the association of cdc2 with cyclin B (Fig 6B) . We then examined the regulation of the JNK1/2 MAPK and p50/p300 pathways in CIL-102-mediated DLD-1 cell cycle arrest, while cells were incubated for 2 h with the specific inhibitors JNK inhibitor SP600125, NF-κB p50 inhibitor (PDTC) and p300/CBP inhibitor C646, and were then treated with CIL-102. The expressions of p21, GADD45, and Ac-Histone H3, as well as the association of cdc2/cyclin B, were analyzed. SP600125, PDTC and C646 significantly reversed the CIL-102-induced expression of p21, GADD45, Ac-Histone H3 and the reduced association of cdc2/cyclin B. Taken together, these results show that CIL-102 induces sustained activation of the JNK1/2 and p50/p300 pathway, GADD45 and p21, and that the apoptotic pathway is required for CIL-102 inhibition of DLD-1 cell growth (Fig 6B) .
Discussion
The development of colorectal cancer (CRC) is a sequential multistage process consisting of tumor initiation, tumor promotion, and tumor metastasis [30] . Despite intense efforts to develop treatments, effective agents have not yet been found. Medicinal herbs or foods are a potential source of chemopreventive compounds for antitumor activities that target the apoptosis pathways in cancer cells that damage DNA and activate the signaling pathways, and for the expression of proteins involved in the growth arrest of cancer cells [5, 11] . Previous studies have shown that anticancer drugs, including Cisplatin, Camptothecin, Etoposide and Doxorubincin, act by inflicting DNA damage. Most of these bioactive compounds are plant secondary metabolites such as terpenoids, flavonoids and alkaloids, all of which kill tumor cells by apoptosis induction [31] . Our in vitro data demonstrated that furo [2,3-b] quinoline derivatives, such as CIL-102, and treatment above a concentration of 1 μM resulted in a significant antiproliferative effect against human colorectal cancer cells but not for normal HCoEpiC cells (Fig 1) . Here, CIL-102 treatment at the concentration of 10 μM for 24 h resulted in an induction of DLD-1 cell apoptosis (Fig 2) . We also found that CIL-102 induced DLD-1 cell accumulation in the G2/M phase (Fig 3) , the same as the effect on other HCT-116 cells (unpublished data). CIL-102 was studied for the mechanism of its action in the apoptotic pathway in the human colonic carcinoma cell. Treatment of CIL-102 resulted in the activation of the caspase 8, caspase 9 and caspase 3, and the release of cytochrome c in the time-dependent induction of apoptosis (Fig 4) . In addition, there was an increase in the cellular levels of phospho JNK1/2, Fas-L and t-BID in the CIL-102-induced apoptosis via the activation of JNK (Figs 4 and 6A) . The induction of apoptosis was alleviated by inhibitors for JNK1/2MAPK (Table 1) . Furthermore, our study demonstrated that the cytotoxic effect of CIL-102 on the DLD-1 appeared to CIL-102-Induced Cell Cycle Arrest and Apoptosis in Colorectal Cancer Cells be through G2/M phase arrest with GADD45 and p21 expression, as well as activation of the p50/p300/CBP pathway, and that it caused a decrease in cd2/cyclin B1 activity (Fig 5) . Additionally, the JNK1/2 and p50/p300 pathways were directly involved in activating GADD45 and p21 during the mitosis transition (Table 1) . CIL-102 activated JNK1/2 and p50/p300 as well as the expression of GADD45 and p21 on DLD-1 following the DNA damage response, suggesting this as a target with CIL-102 (Fig 6B) . Studies have shown that the potential antitumor activity of CIL-102 may be mediated mitotic arrest and apoptosis in human prostate cancer cells via binding to tubulin and disrupting microtubule organization with a variety of signaling pathways [10] . Our previous study demonstrated that CIL-102 inhibited proliferation in human astrocytoma cells by activating the ERK1/2 and Cdc25cSer 216 cell-cycle-related proteins and inducing ROS production, leading to oxidative stress [23, 24] . Therefore, based on this study, by evaluating the apoptosis and mitotic phase arrest involving the signaling pathway, we assayed whether CIL-102 related to growth inhibition and activation of the signaling pathway in human CRC cells provides substantial therapeutic advantages. Recent findings have demonstrated that the overexpression of Gadd45 in human normal fibroblasts causes cells to arrest in the mitotic phase. Cancer cells show abnormality of the cell cycle G2/M checkpoint following exposure to certain DNA-damaging agents [32] . Gadd45 has been shown to interact with cdc2 kinase, which is required for the G2-M transition. The interaction between GADD45 and p21 results in the inhibition of cdc2-cyclin B1 kinase activity [20, 32] . Our results determined that the upregulation of GADD45 and p21 protein affected the G2/M cell cycle arrest of DLD-1 cells with a decrease in the association of the cdc2/cyclin B1 complexes, which was preceded by the JNK1/2MAPK/ NF-κBp50/p300/CBP pathway (Fig 6) . Many studies have shown that cellular mechanisms contribute to the overall cancer-prevention effects of these dietary phytochemicals [33] . Natural phytochemicals from certain plants have the capability to affect the epigenome and can also trigger sustained DNA damage and apoptosis induction. Additionally, they can disrupt the G2/M cell cycle in cancer cells exposed to dietary phytochemicals such as histone deacetylase inhibitors (HDAC) [34] . Inhibition of HDAC activity may occur in human colon cancer lines, with an increase in histone H3 acetylation in global or local histone modification status, such as induction of TRAIL, DR4 and Fas-L, p21 genes, via histone acetyltransferase (HAT) p300/CBP [35, 36] . Furthermore, the current in vitro study demonstrated that CIL-102 treatment significantly upregulated the expression of p300/CBP and acetylation of H3 (Ac-Histone H3) in DLD-1 cells (Figs 5 and 6B) . Thus, CIL-102, as an individual dietary phytochemical, represents a novel chemotherapeutic agent worth continued investigation in the treatment of CRC. Additional studies are still needed to elucidate the CIL-102 effects on the HAT and HDAC between different molecular cellular signaling pathways and epigenetic machinery as well as to determine in vivo CRC cells' xenograft and CIL-102 dose treatment.
In this study, we evaluated CIL-102-induced apoptosis and the cell cycle arrest G2/M phase in human DLD-1 cancer cells as a result of the expression of p21 and GADD45 and cdc2/cyclin B inactivation by the activation of the JNK1/2 signaling pathway and the p50NF-κB/p300/CBP pathway. These results lead us to speculate that CIL-102 may play a role in an apoptotic cascade in DLD-1 cells via Fas-L, t-BID expression and cytochrome c release, and caspase-8, 3, and 9 activation (Fig 7) . This study is potentially interesting with regard to the antitumor effect of CIL-102 as it relates to the development of novel chemotherapeutic approaches in the treatment of malignant CRC. Further study is required.
